KR20220122652A - TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 - Google Patents

TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 Download PDF

Info

Publication number
KR20220122652A
KR20220122652A KR1020227022860A KR20227022860A KR20220122652A KR 20220122652 A KR20220122652 A KR 20220122652A KR 1020227022860 A KR1020227022860 A KR 1020227022860A KR 20227022860 A KR20227022860 A KR 20227022860A KR 20220122652 A KR20220122652 A KR 20220122652A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
ser
isvd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227022860A
Other languages
English (en)
Korean (ko)
Inventor
헤이디 롬멜라에르
크리스티안 아스브란트
안 브리제
시그리드 코르넬리스
에릭 로렌트
Original Assignee
아블린쓰 엔.브이.
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아블린쓰 엔.브이., 사노피 filed Critical 아블린쓰 엔.브이.
Publication of KR20220122652A publication Critical patent/KR20220122652A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227022860A 2019-12-06 2020-12-03 TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 Withdrawn KR20220122652A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962944619P 2019-12-06 2019-12-06
US62/944,619 2019-12-06
EP20305056 2020-01-23
EP20305056.2 2020-01-23
EP20000090.9 2020-02-28
EP20000090 2020-02-28
EP20305216 2020-03-02
EP20305216.2 2020-03-02
PCT/EP2020/084430 WO2021110816A1 (en) 2019-12-06 2020-12-03 POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23

Publications (1)

Publication Number Publication Date
KR20220122652A true KR20220122652A (ko) 2022-09-02

Family

ID=73642903

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227022860A Withdrawn KR20220122652A (ko) 2019-12-06 2020-12-03 TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드

Country Status (14)

Country Link
US (4) US20210188963A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069733A1 (cg-RX-API-DMAC7.html)
JP (1) JP7657797B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220122652A (cg-RX-API-DMAC7.html)
CN (1) CN114981300B (cg-RX-API-DMAC7.html)
AU (1) AU2020396204A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009799A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163877A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022009239A2 (cg-RX-API-DMAC7.html)
IL (1) IL293561A (cg-RX-API-DMAC7.html)
MX (1) MX2022006880A (cg-RX-API-DMAC7.html)
PH (1) PH12022551214A1 (cg-RX-API-DMAC7.html)
TW (1) TW202134269A (cg-RX-API-DMAC7.html)
WO (1) WO2021110816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
EP4069733A1 (en) 2019-12-06 2022-10-12 Ablynx N.V. POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFalpha AND IL-23
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
EP4438614A1 (en) 2023-03-31 2024-10-02 Sanofi Methods for purifying heteromultimeric antibodies
US20250236673A1 (en) * 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
CN118687298A (zh) 2024-07-29 2024-09-24 上海原能细胞生物低温设备有限公司 一种立式低温存储冰箱
CN119371530B (zh) * 2024-11-06 2025-05-20 北京科道博济生物科技有限公司 一种靶向il-23a的纳米抗体及其应用
CN121824755A (zh) * 2026-01-16 2026-04-10 天津科道博济生物科技有限公司 一种靶向il-23a的纳米检测抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CA2706425A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
EP3365371B1 (en) * 2015-10-22 2025-10-08 Ablynx NV Gitr agonists
NO2768984T3 (cg-RX-API-DMAC7.html) 2015-11-12 2018-06-09
HUE057241T2 (hu) 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
EP3414268A1 (en) * 2016-02-12 2018-12-19 Ablynx NV Method for the production of immunoglobulin single variable domains
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
EP4442709A3 (en) 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
EP4069733A1 (en) 2019-12-06 2022-10-12 Ablynx N.V. POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFalpha AND IL-23

Also Published As

Publication number Publication date
US11332525B2 (en) 2022-05-17
CN114981300B (zh) 2025-10-31
US12528860B2 (en) 2026-01-20
EP4069733A1 (en) 2022-10-12
US20220064281A1 (en) 2022-03-03
TW202134269A (zh) 2021-09-16
PH12022551214A1 (en) 2023-10-09
AU2020396204A1 (en) 2022-07-28
BR112022009799A2 (pt) 2022-08-16
US20220363747A1 (en) 2022-11-17
CN114981300A (zh) 2022-08-30
WO2021110816A1 (en) 2021-06-10
JP7657797B2 (ja) 2025-04-07
US20210188963A1 (en) 2021-06-24
CA3163877A1 (en) 2021-06-10
IL293561A (en) 2022-08-01
US20220372128A1 (en) 2022-11-24
JP2023505492A (ja) 2023-02-09
CO2022009239A2 (es) 2022-07-29
MX2022006880A (es) 2022-07-11

Similar Documents

Publication Publication Date Title
US12528860B2 (en) Polypeptides comprising immunoglobulin single variable domains targeting TNFα and IL-23
TWI861302B (zh) 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
US11208476B2 (en) Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
US20210188986A1 (en) Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
US12509522B2 (en) Polypeptides comprising immunoglobulin single variable domains targeting il-13 and OX40L
US11897951B2 (en) Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
RU2846433C1 (ru) Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на tnfa и ox40l
CN116615453A (zh) 包含靶向IL-6和TNF-α的免疫球蛋白单可变结构域的多肽

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301